SINGAPORE, Dec. 8, 2010 /PRNewswire-Asia/ — From the 1st to the
3rd of March 2011, vaccine leaders from developing and developed
world will meet at Vaccine World Summit in New Delhi. The event
will be hosted by IMAPAC, in partnership with DCVMN (Developing
Countries Vaccine Manufacturers Network).
Participants will be discussing strategies to tackle global
public health challenges including appropriate pandemic
surveillance programs, low cost and fast vaccine manufacturing
technologies, innovative adjuvants and delivery systems, vaccine
research funding opportunities and the latest clinical results of
new and next generation vaccines fighting life-threatening
infectious diseases such as cholera, malaria, dengue, AIDS and
rotavirus infection, just to name a few.
As a matter of fact, over 9.5 million people die each
year due to infectious diseases – nearly all live in
Current vaccines and past vaccination programs have now
controlled 10 major infectious diseases. Unfortunately, many of
these diseases, except for smallpox, are still rampant in third
world and developing countries, which can mean a comeback anywhere,
where vaccines begin to be delayed or stopped.
The Indian vaccine industry has always played an important role
in helping the world fight infectious diseases. According to
Biotechnology Industry Organization, the Indian vaccine industry
currently caters to 60 to 70 percent of global requirement of basic
vaccines procured by U.N. agencies for children. In addition to
this, Indian vaccine manufacturers are also partners in several
global initiatives to develop cost-effective vaccines against the
threats of H1N1, meningitis, Japanese encephalitis, etc.
However, challenges such as “access to new technology”,
“increasing cost”, “inadequate disease burden data”, “funding”,
“multiple set of regulation and regulators” still remain as major
stumbling blocks for Indian vaccine manufactur